Oppenheimer on Immuneering: 'believe there's additional upside with upcoming catalyst'

 Oppenheimer analyst Jay Oldon reiterated an Outperform rating and $21.00 price target on Immuneering Corporation (NASDAQ: IMRX)

https://www.streetinsider.com/Analyst+Comments/Oppenheimer+on+Immuneering+Corporation+%28IMRX%29%3A+we+believe+theres+additional+upside+with+this+upcoming+catalyst/25320130.html